Macular Pucker
13
1
1
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.7%
1 terminated out of 13 trials
87.5%
+1.0% vs benchmark
15%
2 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (13)
Surgical Procedure Efficiency Evaluation stuDy
Zeiss RESIGHT Disposable Lenses Evaluation Study
EpiRetinal Membrane Peeling and Internal Limiting Membrane
Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.
Efficacy and Safety Evaluation of MONOBLUE DUAL View and MONOBLUE ILM View Vital Stains
Intraoperative Analysis of the Central Retina in ERF
Compare ELP in Patients With Elective Phaco-VTX Surgery in One Eye and a Single Lens Phaco Surgery on the Other Eye
Inner Nuclear Macular Microcyst is a Risk Factor for Macular Cystoid Changes After Phacoemulsification in Eyes With Previous Vitrectomy and Macular Pucker Removal
Morphologic Changes After Membrane Peeling With Air Tamponade and Balanced Salt Solution
Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study
Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy
Brilliant Blue Versus Indocyanine Green
Membrane Blue Versus Infracyanine Green